Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.35 |
| ▸ | FURIN | P09958 | 8/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | NMT2 | O60551 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20803561 | 0.96 | C3AR1 (0.34) | SIRT6SIRT1SIRT5FURINSMN1; SMN2 | |
| SCHEMBL22692383 | 0.96 | C3AR1 (0.34) | SIRT6SIRT1SIRT5FURINSMN1; SMN2 | |
| SCHEMBL21914903 | 0.96 | C3AR1 (0.34) | SIRT6SIRT1SIRT5FURINSMN1; SMN2 | |
| SCHEMBL24173258 | 0.96 | C3AR1 (0.34) | SIRT6SIRT1SIRT5FURINSMN1; SMN2 | |
| SCHEMBL22198634 | 0.96 | C3AR1 (0.34) | SIRT6SIRT1SIRT5FURINSMN1; SMN2 | |
| SCHEMBL17992599 | 0.96 | C3AR1 (0.34) | SIRT6SIRT1SIRT5FURINSMN1; SMN2 | |
| SCHEMBL21914949 | 0.96 | C3AR1 (0.34) | SIRT6SIRT1SIRT5FURINSMN1; SMN2 | |
| SCHEMBL24172987 | 0.88 | FURIN (0.33) | SIRT5FURINSMN1; SMN2RENLMNA | |
| SCHEMBL23105946 | 0.87 | C3AR1 (0.33) | SIRT6SIRT1SIRT5RENEPHX1 | |
| SCHEMBL21503810 | 0.87 | C3AR1 (0.33) | SIRT6SIRT1SIRT5RENEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | SIRT6 2518/4885SIRT1 3802/4885SIRT5 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.